

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

August 2, 2024



**Consolidated Financial Results
for the Three Months Ended June 30, 2024
(Under Japanese GAAP)**

Company name:	Mochida Pharmaceutical Co., Ltd.
Listing:	Tokyo Stock Exchange
Securities code:	4534
URL:	https://www.mochida.co.jp/english/
Representative:	(Name) Naoyuki Mochida (Title) Representative Director, President
Inquiries:	(Name) Kenichi Miyamoto (Title) Head of Finance & Accounting Department
Telephone:	+81-3-3358-7211
Scheduled date to commence dividend payments:	-
Preparation of supplementary material on financial results:	None
Holding of financial results briefing:	None

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the three months ended June 30, 2024 (from April 1, 2024 to June 30, 2024)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Three months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
June 30, 2024	25,407	2.7	2,189	(13.0)	2,367	(8.7)	1,554	(7.9)
June 30, 2023	24,747	(10.6)	2,515	(41.0)	2,592	(41.3)	1,688	(46.5)

Note:	Comprehensive income	For the three months ended June 30, 2024:	¥848 million	[(65.0)%]
		For the three months ended June 30, 2023:	¥2,427 million	[(26.2)%]

	Basic earnings per share	Diluted earnings per share
Three months ended	Yen	Yen
June 30, 2024	43.85	-
June 30, 2023	46.24	-

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio
As of	Millions of yen	Millions of yen	%
June 30, 2024	158,051	127,396	80.6
March 31, 2024	158,800	127,967	80.6

Reference: Equity

As of June 30, 2024:	¥127,396 million
As of March 31, 2024:	¥127,967 million

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2024	-	40.00	-	40.00	80.00
Fiscal year ending March 31, 2025	-				
Fiscal year ending March 31, 2025 (Forecast)		40.00	-	40.00	80.00

Note: Revisions to the forecast of cash dividends most recently announced: None

3. Consolidated financial result forecasts for the fiscal year ending March 31, 2025 (from April 1, 2024 to March 31, 2025)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	106,000	3.0	7,500	29.3	7,700	27.5	5,600	23.1	157.96

Note: Revisions to the financial result forecast most recently announced: None

* Notes

(1) Significant changes in the scope of consolidation during the period: None

Newly included: - companies (Company name)

Excluded: - companies (Company name)

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: Yes

(3) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(iv) Restatement: None

(4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of June 30, 2024	37,470,000 shares
As of March 31, 2024	37,470,000 shares

(ii) Number of treasury shares at the end of the period

As of June 30, 2024	2,018,759 shares
As of March 31, 2024	2,018,491 shares

(iii) Average number of shares outstanding during the period (cumulative)

Three months ended June 30, 2024	35,451,376 shares
Three months ended June 30, 2023	36,511,601 shares

* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

* Explanation of the proper use of financial result forecasts and other special matters

The financial result forecasts presented in this document are based on information that is currently available to the Company as of the announcement of this document, and the Company does not guarantee to achieve them. In addition, actual financial results may differ significantly from these forecasts due to a wide range of factors.

Quarterly Consolidated Financial Statements

(1) Quarterly Consolidated Balance Sheets

(Millions of yen)

	As of March 31, 2024	As of June 30, 2024
Assets		
Current assets		
Cash and deposits	33,290	36,226
Accounts receivable - trade	34,838	32,617
Securities	13,499	13,499
Merchandise and finished goods	18,535	18,395
Work in process	1,428	2,367
Raw materials and supplies	10,315	10,215
Other	4,753	3,432
Total current assets	116,662	116,753
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	6,823	6,746
Machinery, equipment and vehicles, net	1,667	1,866
Land	5,993	5,993
Other, net	1,390	1,341
Total property, plant and equipment	15,874	15,948
Intangible assets	721	714
Investments and other assets		
Investment securities	16,116	15,100
Deferred tax assets	2,372	2,748
Other	7,052	6,785
Total investments and other assets	25,541	24,634
Total non-current assets	42,138	41,297
Total assets	158,800	158,051

(Millions of yen)

	As of March 31, 2024	As of June 30, 2024
Liabilities		
Current liabilities		
Notes and accounts payable - trade	10,975	9,840
Electronically recorded obligations - operating	1,207	1,152
Income taxes payable	593	928
Provision for bonuses	2,140	992
Other provisions	163	115
Other	10,992	12,894
Total current liabilities	26,073	25,924
Non-current liabilities		
Retirement benefit liability	3,908	3,879
Other	851	850
Total non-current liabilities	4,759	4,730
Total liabilities	30,833	30,654
Net assets		
Shareholders' equity		
Share capital	7,229	7,229
Capital surplus	1,871	1,871
Retained earnings	117,022	117,158
Treasury shares	(7,021)	(7,021)
Total shareholders' equity	119,102	119,237
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	8,585	7,897
Remeasurements of defined benefit plans	279	261
Total accumulated other comprehensive income	8,864	8,158
Total net assets	127,967	127,396
Total liabilities and net assets	158,800	158,051

(2) Quarterly Consolidated Statements of Income and Comprehensive Income

Quarterly Consolidated Statements of Income

Three Months Ended June 30

(Millions of yen)

	For the three months ended June 30, 2023	For the three months ended June 30, 2024
Net sales	24,747	25,407
Cost of sales	11,542	12,451
Gross profit	13,205	12,955
Selling, general and administrative expenses	10,689	10,766
Operating profit	2,515	2,189
Non-operating income		
Interest income	0	0
Dividend income	181	203
Other	36	29
Total non-operating income	218	234
Non-operating expenses		
Interest expenses	0	0
Share of loss of entities accounted for using equity method	43	24
Commission expenses	3	3
Foreign exchange losses	90	25
Other	3	2
Total non-operating expenses	142	56
Ordinary profit	2,592	2,367
Extraordinary income		
Gain on sale of non-current assets	—	1
Settlement income	11	—
Total extraordinary income	11	1
Extraordinary losses		
Loss on sale and retirement of non-current assets	31	4
Total extraordinary losses	31	4
Profit before income taxes	2,572	2,364
Income taxes	884	809
Profit	1,688	1,554
Profit attributable to owners of parent	1,688	1,554

Quarterly Consolidated Statements of Comprehensive Income

Three Months Ended June 30

(Millions of yen)

	For the three months ended June 30, 2023	For the three months ended June 30, 2024
Profit	1,688	1,554
Other comprehensive income		
Valuation difference on available-for-sale securities	750	(687)
Remeasurements of defined benefit plans, net of tax	(11)	(18)
Total other comprehensive income	738	(706)
Comprehensive income	2,427	848
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	2,427	848

Sales of Major Products
(Three months ended June 30, 2024)

(Billions of yen)

Products		Fiscal year ended March 31, 2024		Fiscal year ending March 31, 2025		Three months Y o Y changes %
		Apr-Jun	Apr-Mar	Apr-Jun	Apr-Mar forecast	
Treatment of ulcerative colitis	Lialda®	3.6	14.5	3.7	14.6	+ 3%
Treatment for chronic constipation	Goofice®	1.9	7.7	2.0	9.0	+ 7%
Drug for hyperlipidemia and arteriosclerosis obliterans	Epadel	2.0	7.4	1.5	6.5	△ 25%
Treatment for chronic constipation	Movicol®	1.4	5.9	1.5	6.0	+ 9%
Gout and hyperuricemia	Urece®	0.7	3.3	1.0	5.4	+ 38%
Antidepressant	Lexapro®	1.3	5.2	0.9	3.7	△ 28%
Treatment for pulmonary arterial hypertension	Treprost®	0.4	2.3	1.0	2.8	+ 134%
Analgesic for chronic pain and pain after tooth extraction	Tramcet®	0.6	2.2	0.4	2.0	△ 23%
Calcium channel blocker with a long- acting hypotensive effect	Atelec®	0.6	2.3	0.4	1.8	△ 24%
Treatment of ulcerative colitis	Cortiment®	–	0.2	0.0	1.4	–
Anticoagulant agent	Heparin Sodium MOCHIDA	0.3	1.3	0.3	1.2	+ 1%
Therapeutic agent for endometriosis, adenomyosis and dysmenorrhea	Dinagest	0.2	1.1	0.2	0.7	△ 21%
Generic drugs		7.4	32.6	7.2	28.5	△ 3%
Skin Care Products		1.6	6.4	1.6	6.8	+ 5%

Sales of Atelec® are the sum of Atelec® and Atedio®.

Cortiment® was launched in September 2023.

Development Pipeline

【Ethical drug】

Development code 〈Generic name〉	Stage	Indications	Formulation	Remarks 〈Development country〉
ACT-541468 〈daridorexant〉	Filed	Insomnia	Oral	Co-development with Nxera Pharma Japan Co., Ltd. (Former Idorsia Pharmaceuticals Japan Ltd.) 〈Japan〉
MD-711 〈treprostinil〉	Filed	Pulmonary hypertension associated with interstitial lung disease or combined pulmonary fibrosis and emphysema	Inhalant	Licensed-in from United Therapeutics Corporation In-house development 〈Japan〉
* MD-0901 〈mesalazine〉	Filed	Ulcerative colitis (pediatric indication)	Oral	Licensed-in from Takeda Pharmaceuticals U.S.A., Inc. In-house development 〈Japan〉
FYU-981 〈dotinurad〉	Phase III	Gout and hyperuricemia (pediatric indication)	Oral	Co-development with FUJI YAKUHIN Co., Ltd. 〈Japan〉
* MND-21 〈icosapent〉	Filed	Hypertriglyceridemia	Oral	Collaboration on development with Sumitomo Pharma (Suzhou) Co., Ltd. 〈China〉

【Medical device】

Development code or Product name	Stage	Intended use or indications	Remarks 〈Development country〉
dMD-001	Filed	Articular cartilage lesion	In-house development 〈Japan〉
dMD-002	Therapeutic exploratory study	Cavernous nerve injury	In-house development 〈Japan〉
dMD-003	Therapeutic confirmatory study	Post-operative adhesion	In-house development 〈Japan〉
* ReFeel	Cleared(510(k))	Peripheral nerve injury	In-house development 〈USA〉

Stages of Medical devices are classified into “Therapeutic exploratory study” and “Therapeutic confirmatory study”.

* Updates from May 13, 2024